Andrew W. Stamford

The BACE1 inhibitor verubecestat (MK-8931) reduces CNS β-amyloid in animal models and in Alzheimer’s disease patients

Matthew Kennedy, Andrew W. Stamford, Xia Chen et al. · Science Translational Medicine · 2016 · 417 citations

Life Sciences, Neuroscience, Pharmacology +17

Development of human cGAS-specific small-molecule inhibitors for repression of dsDNA-triggered interferon expression

Lodoe Lama, Carolina Adura, Wei Xie et al. · Nature Communications · 2019 · 283 citations · Full text

Pharmacy, Medicinal Chemistry, Pharmacology +17

Discovery of the 3-Imino-1,2,4-thiadiazinane 1,1-Dioxide Derivative Verubecestat (MK-8931)–A β-Site Amyloid Precursor Protein Cleaving Enzyme 1 Inhibitor for the Treatment of Alzheimer’s Disease

Jack D. Scott, Sarah W. Li, Andrew P. J. Brunskill et al. · Journal of Medicinal Chemistry · 2016 · 165 citations · Full text

Life Sciences, Medicinal Chemistry, Pharmacology +17

Structure based design of iminohydantoin BACE1 inhibitors: Identification of an orally available, centrally active BACE1 inhibitor

Jared N. Cumming, Elizabeth M. Smith, Lingyan Wang et al. · Bioorganic & Medicinal Chemistry Letters · 2012 · 154 citations · Full text

Pharmacy, Medicinal Chemistry, Pharmacology +14

Characterization of the Potent and Highly Selective A2A Receptor Antagonists Preladenant and SCH 412348 [7-[2-[4-2,4-Difluorophenyl]-1-piperazinyl]ethyl]-2-(2-furanyl)-7H-pyrazolo[4,3-e][1,2,4]triazolo[1,5-c]pyrimidin-5-amine] in Rodent Models of Movement Disorders and Depression

Robert A. Hodgson, Rosalia Bertorelli, Geoffrey B. Varty et al. · Journal of Pharmacology and Experimental Therapeutics · 2009 · 149 citations

Medicine, Neuroscience, Pharmacology +17